Surrozen (SRZN) Misses Q1 EPS by 1165c May 7, 2026 09:59AM
TD Cowen Starts Surrozen Inc. (SRZN) at Buy Apr 21, 2026 05:29AM
Guggenheim stays Buy rated on Surrozen Inc. (SRZN) following earnings: 'well-positioned to unlock ~$17B opportunity' Mar 24, 2026 10:47AM
Surrozen (SRZN) Reiterated at Overweight by Cantor Fitzgerald After Post-Q4 Model Update Mar 24, 2026 07:34AM
Surrozen Inc. (SRZN) PT Raised to $36 at H.C. Wainwright Mar 24, 2026 06:38AM


Mar 23, 2026 05:31PM Surrozen (SRZN) files $200M mixed shelf
Feb 19, 2026 06:10AM Cantor Fitzgerald Starts Surrozen Inc. (SRZN) at Overweight
Nov 11, 2025 12:28AM Surrozen (SRZN) reported Q3 result
May 14, 2025 08:31AM Surrozen (SRZN) Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
May 9, 2025 05:05PM Surrozen (SRZN) Misses Q3 EPS by 743c
Mar 24, 2025 09:01AM Surrozen (SRZN) Announces Oversubscribed $175M Private Placement
Jan 30, 2025 06:07AM H.C. Wainwright Starts Surrozen Inc. (SRZN) at Buy, PT $32
Nov 4, 2024 08:32AM Surrozen (SRZN) and TCGFB Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
Sep 24, 2024 08:31AM Surrozen (SRZN) Earns $10M Milestone Payment in Retinal Diseases Collaboration
Aug 13, 2024 04:23PM Surrozen (SRZN) Misses Q2 EPS by 799c
Jun 10, 2024 08:30AM Surrozen (SRZN) Presents Preliminary Results from Phase 1a Study of SZN-043